Understanding respiratory syncytial virus infection to improve treatment and immunity

Current Molecular Medicine

Volumn 13, Issue 7, 2013, Pages 1122-1139

  Gonzalez P A ^a   Carreno L J ^a   Bueno, S M ^a,b   Riedel, C A ^c   Kalergis, A M ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSERM   (France)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Dendritic cells; Immune evasion; Immune modulation; Prophylaxis; T cells; Vaccine; Virus infective cycle

Indexed keywords

1 (2, 3 DIHYDRO 2 OXO 5 PHENYL 1H 1, 4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL) UREA; 1 CYCLOPROPYL 1, 3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL] METHYL] 2H IMIDAZO [4, 5 C] PYRIDIN 2 ONE; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; ALN RSV 01; ANTIVIRUS AGENT; CD8 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; CXCL3 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MBX 300; MONOCYTE CHEMOTACTIC PROTEIN 1; MOTAVIZUMAB; NUCLEOLIN; PALIVIZUMAB; RANTES; RFI 641; RIBAVIRIN; TERIFLUNOMIDE; TMC 353121; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 14637; YM 53403;

ADAPTIVE IMMUNITY; CHILD HOSPITALIZATION; COST EFFECTIVENESS ANALYSIS; CYTOKINE RESPONSE; DENDRITIC CELL; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LIFE CYCLE; MUTATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH PROBLEM; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 84881326943     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313070007     Document Type: Review

References (197)

1. Blount RE, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956; 92: 544-549.
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66: 281-290.
3. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957; 66: 291-300.
4. Storey S. Respiratory syncytial virus market. Nat Rev Drug Discov 2010; 9: 15-16.
5. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998; 11: 430-439.
6. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22: 275-284.
7. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543-546.
8. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300: 530-534.
9. Murata Y. Respiratory syncytial virus infection in adults. Curr Opin Pulm Med 2008; 14: 235-240.
10. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003; 22: S76-S82.
11. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-1555.
12. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7: 719-724.
13. Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 2009; 326: 1279-1283.
14. Hall CB, Douglas RG Jr, Schnabel KC, Geiman JM. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981; 33: 779-783.
15. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001; 289: 283-296.
16. Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 1997; 94: 13961-13966.
17. Techaarpornkul S, Barretto N, Peeples ME. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 2001; 75: 6825-6834.
18. Collarini EJ, Lee FE, Foord O, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009; 183: 6338-6345.
19. Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009; 200: 439-447.
20. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol 2009; 90: 1119-1123.
21. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 2011; 17: 1132-1135.
22. Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: The most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol 2011; 4: 267-275.
23. Ugrinova I, Monier K, Ivaldi C, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol 2007; 8: 66.
24. Cong R, Das S, Ugrinova I, et al. Interaction of nucleolin with ribosomal RNA genes and its role in RNA polymerase I transcription. Nucleic Acids Res 2012; 40: 9441-9454.
25. Wang Y, Mao M, Xu JC. Cell-surface nucleolin is involved in lipopolysaccharide internalization and signalling in alveolar macrophages. Cell Biol Int 2011; 35: 677-685.
26. Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 2008; 17: 813-820.
27. Asenjo A, Gonzalez-Armas JC, Villanueva N. Phosphorylation of human respiratory syncytial virus P protein at serine 54 regulates viral uncoating. Virology 2008; 380: 26-33.
28. Harpen M, Barik T, Musiyenko A, Barik S. Mutational analysis reveals a noncontractile but interactive role of actin and profilin in viral RNA-dependent RNA synthesis. J Virol 2009; 83: 10869-10876.
29. Burke E, Dupuy L, Wall C, Barik S. Role of cellular actin in the gene expression and morphogenesis of human respiratory syncytial virus. Virology 1998; 252: 137-148.
30. Burke E, Mahoney NM, Almo SC, Barik S. Profilin is required for optimal actin-dependent transcription of respiratory syncytial virus genome RNA. J Virol 2000; 74: 669-675.
31. Brown G, Rixon HW, Steel J, et al. Evidence for an association between heat shock protein 70 and the respiratory syncytial virus polymerase complex within lipid-raft membranes during virus infection. Virology 2005; 338: 69-80.
32. Ghildyal R, Ho A, Wagstaff KM, et al. Nuclear import of the respiratory syncytial virus matrix protein is mediated by importin beta1 independent of importin alpha. Biochemistry 2005; 44: 12887-12895.
33. Rodriguez L, Cuesta I, Asenjo A, Villanueva N. Human respiratory syncytial virus matrix protein is an RNA-binding protein: binding properties, location and identity of the RNA contact residues. J Gen Virol 2004; 85: 709-719.
34. Ghildyal R, Baulch-Brown C, Mills J, Meanger J. The matrix protein of Human respiratory syncytial virus localises to the nucleus of infected cells and inhibits transcription. Arch Virol 2003; 148: 1419-1429.
35. Ghildyal R, Ho A, Dias M, et al. The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism. J Virol 2009; 83: 5353-5362.
36. Brown G, Jeffree CE, McDonald T, Mc LRHW, Aitken JD, Sugrue RJ. Analysis of the interaction between respiratory syncytial virus and lipid-rafts in Hep2 cells during infection. Virology 2004; 327: 175-185.
37. Fleming EH, Kolokoltsov AA, Davey RA, Nichols JE, Roberts NJ. Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins. J Virol 2006; 80: 12160-12170.
38. Yeo DS, Chan R, Brown G, et al. Evidence that selective changes in the lipid composition of raft-membranes occur during respiratory syncytial virus infection. Virology 2009; 386: 168-182.
39. Marty A, Meanger J, Mills J, Shields B, Ghildyal R. Association of matrix protein of respiratory syncytial virus with the host cell membrane of infected cells. Arch Virol 2004; 149: 199-210.
40. Kallewaard NL, Bowen AL, Crowe JE. Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus. Virology 2005; 331: 73-81.
41. Radhakrishnan A, Yeo D, Brown G, et al. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol Cell Proteomics 2010; 9: 1829-1848.
42. Utley TJ, Ducharme NA, Varthakavi V, et al. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2. Proc Natl Acad Sci USA 2008; 105: 10209-10214.
43. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
44. Niimi K, Asano K, Shiraishi Y, et al. TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA. J Immunol 2007; 178: 489-495.
45. Lindemans C, Kimpen J, Bont L. The role of toll pathways in viral respiratory disease during early childhood. Curr Mol Med 2009; 9: 519-526.
46. Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83: 1492-1500.
47. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001; 184: 393-399.
48. Tripp RA, Oshansky C, Alvarez R. Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2005; 2: 147-149.
49. Oshansky CM, Barber JP, Crabtree J, Tripp RA. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 2010; 201: 1201-1207.
50. Culley FJ, Pennycook AM, Tregoning JS, et al. Role of CCL5 (RANTES) in viral lung disease. J Virol 2006; 80: 8151-8157.
51. Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, et al. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur Cytokine Netw 2007; 18: 162-167.
52. Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 1999; 163: 2816-2820.
53. Bueno SM, Gonzalez PA, Riedel CA, Carreno LJ, Vasquez AE, Kalergis AM. Local cytokine response upon respiratory syncytial virus infection. Immunol Lett 2011; 136: 122-129.
54. Bueno SM, Gonzalez PA, Pacheco R, et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008; 8: 1320-1329.
55. Peng SC, Wong DS, Tung KC, et al. Computational modeling with forward and reverse engineering links signaling network and genomic regulatory responses: NF-kappaB signaling-induced gene expression responses in inflammation. BMC Bioinformatics 2010; 11: 308.
56. Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA 2008; 105: 20822-20827.
57. Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol 2010; 185: 7633-7645.
58. Scott R, Kaul A, Scott M, Chiba Y, Ogra PL. Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans. J Infect Dis 1978; 137: 810-817.
59. Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976; 10: 75-78.
60. Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182: 4865-4873.
61. Dodd J, Riffault S, Kodituwakku JS, Hayday AC, Openshaw PJ. Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol 2009; 182: 1174-1181.
62. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008; 26: 2020-2033.
63. Kolli D, Bataki EL, Spetch L, et al. T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection. J Virol 2008; 82: 8560-8569.
64. Frey S, Krempl CD, Schmitt-Graff A, Ehl S. Role of T cells in virus control and disease after infection with pneumonia virus of mice. J Virol 2008; 82: 11619-11627.
65. Shishkova Y, Harms H, Krohne G, Avota E, Schneider-Schaulies S. Immune synapses formed with measles virus-infected dendritic cells are unstable and fail to sustain T cell activation. Cell Microbiol 2007; 9: 1974-1986.
66. Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 2008; 181: 7958-7968.
67. Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med 2002; 8: 54-60.
68. Chang J, Choi SY, Jin HT, Sung YC, Braciale TJ. Improved effector activity and memory CD8 T cell development by IL-2 expression during experimental respiratory syncytial virus infection. J Immunol 2004; 172: 503-508.
69. Dakhama A, Vitalis TZ, Hegele RG. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis. Eur Respir J 1997; 10: 20-26.
70. DiNapoli JM, Murphy BR, Collins PL, Bukreyev A. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virol J 2008; 5: 105.
71. Vallbracht S, Unsold H, Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur J Immunol 2006; 36: 1434-1442.
72. Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001; 15: 637-646.
73. Wan YY, Flavell RA. How diverse-CD4 effector T cells and their functions. J Mol Cell Biol 2009; 1: 20-36.
74. Singleton R, Etchart N, Hou S, Hyland L. Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. J Virol 2003; 77: 11303-11311.
75. Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA 2008; 105: 20822-20827.
76. Sutton TC, Tayyari F, Khan MA, Manson HE, Hegele RG. T helper 1 background protects against airway hyperresponsiveness and inflammation in guinea pigs with persistent respiratory syncytial virus infection. Pediatr Res 2007; 61: 525-529.
77. Cyr SL, Jones T, Stoica-Popescu I, et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 2007; 25: 5378-5389.
78. Zeng R, Zhang Z, Mei X, Gong W, Wei L. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice. Biochem Biophys Res Commun 2008; 377: 495-499.
79. Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J Virol 2001; 75: 12128-12140.
80. Bukreyev A, Whitehead SS, Prussin C, Murphy BR, Collins PL. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines. J Virol 2000; 74: 7151-7157.
81. Voges B, Vallbracht S, Zimmer G, et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell Immunol 2007; 247: 85-94.
82. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996; 70: 7783-7791.
83. Tripp RA, Jones LP, Haynes LM, Zheng HQ, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2: 732-738.
84. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses. J Immunol 2006; 176: 1600-1608.
85. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999; 103: 630-636.
86. Siezen CL, Bont L, Hodemaekers HM, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J 2009; 28: 333-335.
87. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003; 143: S118-S126.
88. de Graaff PM, de Jong EC, van Capel TM, et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol 2005; 175: 5904-5911.
89. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009; 83: 3019-3028.
90. Rothoeft T, Fischer K, Zawatzki S, Schulz V, Schauer U, Korner Rettberg C. Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus. Clin Exp Immunol 2007; 150: 263-273.
91. Kauth M, Grage-Griebenow E, Rohde G, et al. Synergistically upregulated interleukin-10 production in cocultures of monocytes and T cells after stimulation with respiratory syncytial virus. Int Arch Allergy Immunol 2007; 142: 116-126.
92. Ostler T, Pircher H, Ehl S. Bystander recruitment of systemic memory T cells delays the immune response to respiratory virus infection. Eur J Immunol 2003; 33: 1839-1848.
93. Schlender J, Walliser G, Fricke J, Conzelmann KK. Respiratory Syncytial Virus Fusion Protein Mediates Inhibition of Mitogen-Induced T-Cell Proliferation by Contact. J Virol 2002; 76: 1163-1170.
94. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
95. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007; 141: 137-145.
96. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58.
97. Tobar JA, Gonzalez PA, Kalergis AM. Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. J Immunol 2004; 173: 4058-4065.
98. Bueno SM, Tobar JA, Iruretagoyena MI, Kalergis AM. Molecular interactions between dendritic cells and Salmonella: escape from adaptive immunity and implications on pathogenesis. Crit Rev Immunol 2005; 25: 389-403.
99. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol 2008; 180: 4836-4837.
100. Majumder B, Janket ML, Schafer EA, et al. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J Virol 2005; 79: 7990-8003.
101. Tobar JA, Carreno LJ, Bueno SM, et al. Virulent Salmonella enterica serovar typhimurium evades adaptive immunity by preventing dendritic cells from activating T cells. Infect Immun 2006; 74: 6438-6448.
102. Carreno LJ, Bueno SM, Bull P, Nathenson SG, Kalergis AM. The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology 2007; 121: 227-237.
103. Bueno SM, Gonzalez PA, Schwebach JR, Kalergis AM. T cell immunity evasion by virulent Salmonella enterica. Immunol Lett 2007; 111: 14-20.
104. Gonzalez PA, Carreno LJ, Figueroa CA, Kalergis AM. Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine Growth Factor Rev 2007; 18: 19-31.
105. Gonzalez PA, Bueno SM, Riedel CA, Kalergis AM. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009; 16: 4609-4625.
106. Guerrero-Plata A, Casola A, Suarez G, et al. Differential Response of Dendritic Cells to Human Metapneumovirus and Respiratory Syncytial Virus. Am. J. Respir. Cell Mol Biol 2006; 34: 320-329.
107. Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA 2008; 105: 14999-15004.
108. Le Nouen C, Munir S, Losq S, et al. Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology 2009; 385: 169-182.
109. Boogaard I, van Oosten M, van Rijt LS, et al. Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. Immunology 2007; 122: 65-72.
110. Gill MA, Palucka AK, Barton T, et al. Mobilization of Plasmacytoid and Myeloid Dendritic Cells to Mucosal Sites in Children with Respiratory Syncytial Virus and Other Viral Respiratory Infections. J Infect Dis 2005; 1991: 1105-1115.
111. Beyer M, Bartz H, Hörner K, Doths S, Koerner-Rettberg C, Schwarze J. Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol 2004; 113: 127-133.
112. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006; 203: 1153-1159.
113. van Rijt LS, Jung S, Kleinjan A, et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005; 201: 981-991.
114. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol 2008; 82: 8780-8796.
115. Wang H, Peters N, Laza-Stanca V, Nawroly N, Johnston SL, Schwarze J. Local CD11c+ MHC Class II- Precursors Generate Lung Dendritic Cells during Respiratory Viral Infection, but are Depleted in the Process. J Immunol 2006; 177: 2536-2542.
116. Wang H, Peters N, Schwarze J. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. J Immunol 2006; 177: 6263-6270.
117. Smit JJ, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 2008; 3: e1720.
118. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006; 203: 1153-1159.
119. Chi B, Dickensheets HL, Spann KM, et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 2006; 80: 5032-5040.
120. Bartz H, Turkel O, Hoffjan S, Rothoeft T, Gonschorek A, Schauer U. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naive T cells. Immunology 2003; 109: 49-57.
121. Dustin ML. T-cell activation through immunological synapses and kinapses. Immunol Rev 2008; 221: 77-89.
122. Huppa JB, Gleimer M, Sumen C, Davis MM. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 2003; 4: 749-755.
123. Carreno LJ, Riquelme EM, Gonzalez PA, et al. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proc Natl Acad Sci USA 2010; 107: 210-215.
124. Cemerski S, Das J, Giurisato E, et al. The balance between T cell receptor signaling and degradation at the center of the immunological synapse is determined by antigen quality. Immunity 2008; 29: 414-422.
125. Fukumoto R, Dundr M, Nicot C, et al. Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J Virol 2007; 81: 9088-9099.
126. Thoulouze MI, Sol-Foulon N, Blanchet F, Dautry-Varsat A, Schwartz O, Alcover A. Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity 2006; 24: 547-561.
127. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004; 431: 527-532.
128. Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol 2000; 165: 15-19.
129. Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010; 50: 1258-1267.
130. Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs 2009; 14: 207-217.
131. Kimura K, Mori S, Tomita K, et al. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res 2000; 47: 41-51.
132. Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004; 48: 413-422.
133. Huntley CC, Weiss WJ, Gazumyan A, et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 2002; 46: 841-847.
134. Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 2003; 77: 5054-5064.
135. Douglas JL, Panis ML, Ho E, et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 2005; 49: 2460-2466.
136. Andries K, Moeremans M, Gevers T, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 2003; 60: 209-219.
137. Bonfanti JF, Meyer C, Doublet F, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 2008; 51: 875-896.
138. Bonfanti JF, Doublet F, Fortin J, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. J Med Chem 2007; 50: 4572-4584.
139. Olszewska W, Ispas G, Schnoeller C, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 2011; 38: 401-408.
140. Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J 2005; 272: 4646-4659.
141. Take M, Tsutsui J, Obama H, et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994; 116: 1063-1068.
142. Legrand D, Vigie K, Said EA, et al. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 2004; 271: 303-317.
143. Nisole S, Krust B, Callebaut C, et al. The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans. J Biol Chem 1999; 274: 27875-27884.
144. Girvan AC, Teng Y, Casson LK, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 2006; 5: 1790-1799.
145. Drygin D, Siddiqui-Jain A, O'Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res 2009; 69: 7653-7661.
146. Henderson EA, Alber DG, Baxter RC, et al. 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 2007; 50: 1685-1692.
147. Sudo K, Miyazaki Y, Kojima N, et al. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 2005; 65: 125-131.
148. Bonavia A, Franti M, Pusateri Keaney E, et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011; 108: 6739-6744.
149. Barik S. Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. Methods Mol Biol 2009; 487: 331-341.
150. Zhang W, Tripp RA. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol 2008; 82: 12221-12231.
151. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
152. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107: 8800-8805.
153. Dunn MC, Knight DA, Waldman WJ. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 2011; 16: 309-317.
154. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422-434.
155. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007: CD000181.
156. Welliver RC. Respiratory syncytial virus infection: therapy and prevention. Paediatr Respir Rev 2004; 5 Suppl A: S127-S133.
157. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
158. Thomas M, Bedford-Russell A, Sharland M. Prevention of respiratory syncytial virus infection with palivizumab. Monaldi Arch Chest Dis 2000; 55: 333-338.
159. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18: 223-231.
160. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368: 652-665.
161. Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009; 28: 267-272.
162. Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70: 186-191.
163. Fernandez P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 2010; 10: 38.
164. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163: 693-698.
165. Kawasaki Y, Hosoya M, Katayose M, Suzuki H. Role of serum neutralizing antibody in reinfection of respiratory syncytial virus. Pediatr Int 2004; 46: 126-129.
166. Handforth J, Friedland JS, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatr Respir Rev 2000; 1: 210-224.
167. Herrada AA, Contreras FJ, Tobar JA, Pacheco R, Kalergis AM. Immune complex-induced enhancement of bacterial antigen presentation requires Fcgamma receptor III expression on dendritic cells. Proc Natl Acad Sci USA 2007; 104: 13402-13407.
168. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195: 1653-1659.
169. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001; 14: 757-764.
170. Everard ML, Swarbrick A, Rigby AS, Milner AD. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. Respir Med 2001; 95: 275-280.
171. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract. Cochrane Database Syst Rev 2000: CD000181.
172. Elliott MB, Pryharski KS, Yu Q, et al. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol 2004; 78: 8446-8454.
173. Park EK, Soh BY, Jang YS, Park JH, Chung GH. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. Mol Cells 2001; 12: 50-56.
174. Bembridge GP, Lopez JA, Bustos R, et al. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. J Virol 1999; 73: 10086-10094.
175. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999; 73: 7099-7197.
176. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996; 70: 7783-7791.
177. Jackson M, Scott R. Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. J Med Virol 1996; 49: 161-169.
178. Crowe JE, Randolph V, Murphy BR. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo. Virus Res 1999; 59: 13-22.
179. Crowe JE, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11: 1395-1404.
180. Whitehead SS, Firestone CY, Collins PL, Murphy BR. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998; 247: 232-239.
181. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182: 1331-1342.
182. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000; 273: 210-218.
183. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J 2010; 7: 114.
184. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997; 71: 8973-8982.
185. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191: 1093-1104.
186. Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res 2012; 169: 38-47.
187. Luongo C, Yang L, Winter CC, et al. Codon stabilization analysis of the 248 temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 2009; 27: 5667-5676.
188. Luongo C, Winter CC, Collins PL, Buchholz UJ. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012; 86: 10792-10804.
189. Elliott MB, Pryharski KS, Yu Q, et al. Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol 2004; 78: 5773-5783.
190. Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 1990; 8: 164-168.
191. Tang RS, Spaete RR, Thompson MW, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008; 26: 6373-6382.
192. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009; 28: 655-658.
193. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31: 109-114.
194. Etchart N, Baaten B, Andersen SR, Hyland L, Wong SY, Hou S. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 2006; 36: 1136-1144.
195. Xie C, He JS, Zhang M, et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 2007; 18: 746-752.
196. Haas MJ. Besieging RSV. SciBX 2009; 2: 7-9.
197. Bueno SM, Gonzalez PA, Kalergis AM. Use of genetically modified bacteria to modulate adaptive immunity. Curr Gene Ther 2009; 9: 171-184.